Kestra Medical Technologies (NASDAQ:KMTS) Stock Price Up 7.8% - Should You Buy?

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - Get Free Report)'s stock price rose 7.8% during trading on Thursday . The stock traded as high as $16.70 and last traded at $16.54. Approximately 395,029 shares were traded during mid-day trading, an increase of 49% from the average daily volume of 265,872 shares. The stock had previously closed at $15.35.

Analyst Ratings Changes

Several research firms recently weighed in on KMTS. Stifel Nicolaus began coverage on shares of Kestra Medical Technologies in a research report on Monday, March 31st. They set a "buy" rating and a $28.00 price target for the company. Bank of America began coverage on shares of Kestra Medical Technologies in a report on Monday, March 31st. They set a "buy" rating and a $30.00 price objective on the stock. Piper Sandler began coverage on shares of Kestra Medical Technologies in a report on Monday, March 31st. They set an "overweight" rating and a $27.00 price objective on the stock. The Goldman Sachs Group dropped their price objective on shares of Kestra Medical Technologies from $24.00 to $23.00 and set a "neutral" rating on the stock in a report on Wednesday, April 16th. Finally, Wells Fargo & Company lowered their price target on shares of Kestra Medical Technologies from $28.00 to $27.00 and set an "overweight" rating on the stock in a report on Thursday. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $27.33.

Kestra Medical Technologies Stock Up 7.2%

The business's 50-day moving average price is $19.02.

Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report) last announced its quarterly earnings data on Monday, April 14th. The company reported ($1.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by ($0.61). During the same quarter in the previous year, the business posted ($1.18) earnings per share.

Institutional Trading of Kestra Medical Technologies

Several institutional investors and hedge funds have recently made changes to their positions in the business. Caas Capital Management LP bought a new position in shares of Kestra Medical Technologies during the first quarter worth approximately $1,470,000. Brown Advisory Inc. acquired a new position in shares of Kestra Medical Technologies during the first quarter worth $13,716,000. Eventide Asset Management LLC acquired a new position in Kestra Medical Technologies in the first quarter valued at $6,853,000. Russell Investments Group Ltd. acquired a new position in Kestra Medical Technologies in the first quarter valued at $457,000. Finally, Armistice Capital LLC bought a new stake in Kestra Medical Technologies in the first quarter valued at $312,000.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.